Antibody Discovery Services

Accelerate lead identification with the only integrated discovery platform that can combine REpAb® polyclonal antibody sequencing with B cell sequencing, phage display, and/or AI-driven analysis.

Antibody Discovery Demands More Than Throughput.

Most antibody discovery campaigns do not get a clear understanding of molecular behavior until late in the process, after clones are expressed and validated.

A unified approach is needed to intelligently pre-select antibodies, without limiting diversity, to prevent wasted efforts or loss of valuable hits.

Protein-first Pre-Selection of Antibodies.

Sequence functional antibody proteins from the immunoserum

Our REpAb® polyclonal antibody sequencing technology uses mass spectrometry and AI to derive the sequences of antigen specific mAbs from a complex mixture. REpAb® can be used on its own, or in combination with B cell sequencing, phage display and predictive AI techniques:

  • More information – directly about the mAb phenotype
  • Selection – earlier in the discovery process
  • Cheaper / faster – reduce cost of expression and assays

Pre-select without unintentional limits to diversity

Access the whole diversity of 1018 mAbs produced in vivo, and use REpAb® to pre-select for:

  • Antigen binding

  • Epitope specific binding

  • Avoiding off-target binding

  • Stability in vivo

  • Functional at relevant pH, temperature

  • Neutralizing

With REpAb®, phenotypic selection happens prior to sequencing, prior to expressing and testing recombinants. Avoid unintentional limits to diversity caused by library or primer design, B cell death, or equipment capacity.

Identification of broadly inhibitory anti-PfEMP1 antibodies by mass spectrometry sequencing of plasma IgG from a malaria-exposed child

 

Antibody Discovery Platform Technologies.

Supported Animal Models

We have experience working with Mouse (single-chain humanized), Human, Camelid (Llama, Alpaca), Rabbit, Chicken, Goat, Sheep, Cow, and Dog. Our platform is not limited by availability of primers, and we can work in practically any species.

Supported Discovery Methods

Combine orthogonal approaches to antibody discovery to expand diversity and save time and expense on costly expression and validation.

Mass Spectrometry

Sequence functional antibody proteins from serum.

B-Cell Sequencing

Use single b-cell sequencing and/or BCR sequencing.

Phage Display / Library

Custom immunized library

AI Generative

Integrate the latest predictive AI to transform your workflow.

Antibody Discovery Workflow.

Use the complete REpAb® Antibody Discovery Pipeline to go from antigen to final antibody candidates in as little as 12 weeks. REpAb® can start with just a pAb (de novo sequencing via mass spectrometry), or combining de novo sequencing with B cell repertoire sequencing (de novo + NGS).

Or, bolt-on REpAb® to your existing antibody discovery pipeline, to get proteomics pre-selection without increasing cycle time. Pre-selection saves recombinant expression and validation costs, and improves success rate 10X.

Antibody Discovery Service Success Stories.

0+
Projects
0
Species
0
Antigen types
0%
Success rate

“Rapid Novor was tasked with finding highly specific, high affinity antibodies against an important target- and they delivered powerful antibodies fit-for-purpose. Such antibodies are not easily obtained yet the Rapid Novor approach proved immediately successful, despite our time-constrained and stringent demands.”

Matt Pope, CEO, SISCAPA

Purpose Built Workflows.

Faster Camelid / VHH Antibody Discovery

A protein-first strategy that identifies functional antibodies that have already undergone in vivo affinity maturation, thereby eliminating the need for B cell availability and the library-construction biases inherent to conventional phage display approaches.

Direct in Human Antibody Discovery

Searching for a therapeutic antibody that works in humans? Start with human antibodies. Bypass the limited diversity of transgenic animals, and humanization risks. Start with convalescent plasma or post-vaccination plasma.

Anti-Idiotype Antibody Discovery

Our approach avoids needle-in-haystack searches through thousands of antibodies to find highly specific mAbs to the drug. Proven to outperform the best.

Custom Antibody Development

Start by generating a custom polyclonal antibody against your target. In parallel with your assay development, you can convert the high performance pAb to a mAb or mAb cocktail.

Talk to Our Scientists.

We Have Sequenced 10,000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.